+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Ovarian Cancer - Pipeline Review, H2 2016

  • ID: 4020178
  • Report
  • December 2016
  • 1887 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • ATLAB Pharma SAS
  • Compliment Corp
  • HEC Pharm Co Ltd
  • Merck KGaA
  • OSE Immunotherapeutics
  • MORE
Ovarian Cancer - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 15, 115, 119, 7, 195, 31 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 11, 34 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • ATLAB Pharma SAS
  • Compliment Corp
  • HEC Pharm Co Ltd
  • Merck KGaA
  • OSE Immunotherapeutics
  • MORE
Introduction

Ovarian Cancer Overview

Therapeutics Development

Ovarian Cancer - Therapeutics under Development by Companies

Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes

Ovarian Cancer - Pipeline Products Glance

Ovarian Cancer - Products under Development by Companies

Ovarian Cancer - Products under Investigation by Universities/Institutes

Ovarian Cancer - Companies Involved in Therapeutics Development

Ovarian Cancer - Therapeutics Assessment

Drug Profiles

Ovarian Cancer - Dormant Projects

Ovarian Cancer - Discontinued Products

Ovarian Cancer - Product Development Milestones

Appendix

List of Tables:

Number of Products under Development for Ovarian Cancer, H2 2016

Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Development by Companies, H2 2016 (Contd..3)

Number of Products under Development by Companies, H2 2016 (Contd..4)

Number of Products under Development by Companies, H2 2016 (Contd..5)

Number of Products under Development by Companies, H2 2016 (Contd..6)

Number of Products under Development by Companies, H2 2016 (Contd..7)

Number of Products under Development by Companies, H2 2016 (Contd..8)

Number of Products under Development by Companies, H2 2016 (Contd..9)

Number of Products under Development by Companies, H2 2016 (Contd..10)

Number of Products under Development by Companies, H2 2016 (Contd..11)

Number of Products under Development by Companies, H2 2016 (Contd..12)

Number of Products under Development by Companies, H2 2016 (Contd..13)

Number of Products under Development by Companies, H2 2016 (Contd..14)

Number of Products under Development by Companies, H2 2016 (Contd..15)

Number of Products under Development by Companies, H2 2016 (Contd..16)

Number of Products under Development by Companies, H2 2016 (Contd..17)

Number of Products under Development by Companies, H2 2016 (Contd..18)

Number of Products under Development by Companies, H2 2016 (Contd..19)

Number of Products under Development by Companies, H2 2016 (Contd..20)

Number of Products under Development by Companies, H2 2016 (Contd..21)

Number of Products under Development by Companies, H2 2016 (Contd..22)

Number of Products under Investigation by Universities/Institutes, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Development by Companies, H2 2016 (Contd..5)

Products under Development by Companies, H2 2016 (Contd..6)

Products under Development by Companies, H2 2016 (Contd..7)

Products under Development by Companies, H2 2016 (Contd..8)

Products under Development by Companies, H2 2016 (Contd..9)

Products under Development by Companies, H2 2016 (Contd..10)

Products under Development by Companies, H2 2016 (Contd..11)

Products under Development by Companies, H2 2016 (Contd..12)

Products under Development by Companies, H2 2016 (Contd..13)

Products under Development by Companies, H2 2016 (Contd..14)

Products under Development by Companies, H2 2016 (Contd..15)

Products under Development by Companies, H2 2016 (Contd..16)

Products under Development by Companies, H2 2016 (Contd..17)

Products under Development by Companies, H2 2016 (Contd..18)

Products under Development by Companies, H2 2016 (Contd..19)

Products under Development by Companies, H2 2016 (Contd..20)

Products under Development by Companies, H2 2016 (Contd..21)

Products under Development by Companies, H2 2016 (Contd..22)

Products under Development by Companies, H2 2016 (Contd..23)

Products under Development by Companies, H2 2016 (Contd..24)

Products under Development by Companies, H2 2016 (Contd..25)

Products under Development by Companies, H2 2016 (Contd..26)

Products under Development by Companies, H2 2016 (Contd..27)

Products under Development by Companies, H2 2016 (Contd..28)

Products under Development by Companies, H2 2016 (Contd..29)

Products under Development by Companies, H2 2016 (Contd..30)

Products under Development by Companies, H2 2016 (Contd..31)

Products under Development by Companies, H2 2016 (Contd..32)

Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)

Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H2 2016

Ovarian Cancer - Pipeline by 4SC AG, H2 2016

Ovarian Cancer - Pipeline by AB Science SA, H2 2016

Ovarian Cancer - Pipeline by AbbVie Inc, H2 2016

Ovarian Cancer - Pipeline by AbGenomics International Inc, H2 2016

Ovarian Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016

Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016

Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016

Ovarian Cancer - Pipeline by Aduro BioTech Inc, H2 2016

Ovarian Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016

Ovarian Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016

Ovarian Cancer - Pipeline by Advaxis Inc, H2 2016

Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016

Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016

Ovarian Cancer - Pipeline by Alchemia Ltd, H2 2016

Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016

Ovarian Cancer - Pipeline by Almac Discovery Ltd, H2 2016

Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H2 2016

Ovarian Cancer - Pipeline by Alteogen Inc, H2 2016

Ovarian Cancer - Pipeline by Ambrx Inc, H2 2016

Ovarian Cancer - Pipeline by Amgen Inc, H2 2016

Ovarian Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016

Ovarian Cancer - Pipeline by ANP Technologies Inc, H2 2016

Ovarian Cancer - Pipeline by AntiCancer Inc, H2 2016

Ovarian Cancer - Pipeline by Antoxis Ltd, H2 2016

Ovarian Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016

Ovarian Cancer - Pipeline by Aphios Corp, H2 2016

Ovarian Cancer - Pipeline by Aposense Ltd, H2 2016

Ovarian Cancer - Pipeline by Aprea AB, H2 2016

Ovarian Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016

Ovarian Cancer - Pipeline by arGEN-X BV, H2 2016

Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H2 2016

Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H2 2016

Ovarian Cancer - Pipeline by Arno Therapeutics Inc, H2 2016

Ovarian Cancer - Pipeline by Arog Pharmaceuticals Inc, H2 2016

Ovarian Cancer - Pipeline by ArQule Inc, H2 2016

Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016

Ovarian Cancer - Pipeline by Arvinas Inc, H2 2016

Ovarian Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016

Ovarian Cancer - Pipeline by Astellas Pharma Inc, H2 2016

Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016

Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2016

Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2016

Ovarian Cancer - Pipeline by Athenex Inc, H2 2016

Ovarian Cancer - Pipeline by ATLAB Pharma SAS, H2 2016

Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016

Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2 2016

Ovarian Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016

Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016

Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2 2016

Ovarian Cancer - Pipeline by Bayer AG, H2 2016

Ovarian Cancer - Pipeline by BeiGene Ltd, H2 2016

Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016

Ovarian Cancer - Pipeline by BioCancell Ltd, H2 2016

Ovarian Cancer - Pipeline by BioMoti Ltd, H2 2016

Ovarian Cancer - Pipeline by Bionomics Ltd, H2 2016

Ovarian Cancer - Pipeline by BioNTech AG, H2 2016

Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2016

Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Ovarian Cancer - Pipeline by Boston Biomedical Inc, H2 2016

Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016

Ovarian Cancer - Pipeline by Calithera Biosciences Inc, H2 2016

Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016

Ovarian Cancer - Pipeline by Cavion LLC, H2 2016

Ovarian Cancer - Pipeline by Cellceutix Corp, H2 2016

Ovarian Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016

Ovarian Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016

Ovarian Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016

Ovarian Cancer - Pipeline by Celon Pharma SA, H2 2016

Ovarian Cancer - Pipeline by Celprogen Inc, H2 2016

Ovarian Cancer - Pipeline by Celsion Corp, H2 2016

Ovarian Cancer - Pipeline by Celyad SA, H2 2016

Ovarian Cancer - Pipeline by Ceronco Biosciences, H2 2016

Ovarian Cancer - Pipeline by CerRx Inc, H2 2016

Ovarian Cancer - Pipeline by Cerulean Pharma Inc, H2 2016

Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016

Ovarian Cancer - Pipeline by Cielo Therapeutics Inc, H2 2016

Ovarian Cancer - Pipeline by Clovis Oncology Inc, H2 2016

Ovarian Cancer - Pipeline by CohBar Inc, H2 2016

Ovarian Cancer - Pipeline by Coherus BioSciences Inc, H2 2016

Ovarian Cancer - Pipeline by Commence Bio Inc, H2 2016

Ovarian Cancer - Pipeline by Compliment Corp, H2 2016

List of Figures:

Number of Products under Development for Ovarian Cancer, H2 2016

Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Top 10 Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
4 of 5
  • 3-V Biosciences Inc
  • 4SC AG
  • AB Science SA
  • AbbVie Inc
  • AbGenomics International Inc
  • Acetylon Pharmaceuticals Inc
  • Adaptimmune Therapeutics Plc
  • Adgero Biopharmaceuticals Inc
  • Aduro BioTech Inc
  • Advanced Accelerator Applications SA
  • Advanced Cancer Therapeutics
  • Advaxis Inc
  • Advenchen Laboratories LLC
  • Aeterna Zentaris Inc
  • Alchemia Ltd
  • Alethia Biotherapeutics Inc
  • Almac Discovery Ltd
  • Alpha Cancer Technologies Inc
  • Alteogen Inc
  • Ambrx Inc
  • Amgen Inc
  • Anavex Life Sciences Corp
  • ANP Technologies Inc
  • AntiCancer Inc
  • Antoxis Ltd
  • Apac Biotech Pvt Ltd
  • Aphios Corp
  • Aposense Ltd
  • Aprea AB
  • Aptevo Therapeutics Inc
  • arGEN-X BV
  • ARMO Biosciences Inc
  • Armour Therapeutics Inc
  • Arno Therapeutics Inc
  • Arog Pharmaceuticals Inc
  • ArQule Inc
  • Arrien Pharmaceuticals LLC
  • Arvinas Inc
  • Ascentage Pharma Group Corp Ltd
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Athenex Inc
  • ATLAB Pharma SAS
  • AVEO Pharmaceuticals Inc
  • Avipep Pty Ltd
  • Azaya Therapeutics Inc
  • Basilea Pharmaceutica Ltd
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Bio-Path Holdings Inc
  • BioCancell Ltd
  • BioMoti Ltd
  • Bionomics Ltd
  • BioNTech AG
  • Biscayne Pharmaceuticals Inc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Company
  • Calithera Biosciences Inc
  • CASI Pharmaceuticals Inc
  • Cavion LLC
  • Cellceutix Corp
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Cellular Biomedicine Group Inc
  • Celon Pharma SA
  • Celprogen Inc
  • Celsion Corp
  • Celyad SA
  • Ceronco Biosciences
  • CerRx Inc
  • Cerulean Pharma Inc
  • Chipscreen Biosciences Ltd
  • Cielo Therapeutics Inc
  • Clovis Oncology Inc
  • CohBar Inc
  • Coherus BioSciences Inc
  • Commence Bio Inc
  • Compliment Corp
  • Corcept Therapeutics Inc
  • Critical Outcome Technologies Inc
  • CTI BioPharma Corp
  • Cyclacel Pharmaceuticals Inc
  • CytRx Corp
  • CZ BioMed Corp
  • Deciphera Pharmaceuticals LLC
  • DEKK-TEC Inc
  • DelMar Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Ltd
  • Ecrins Therapeutics SAS
  • EirGenix Inc
  • Eisai Co Ltd
  • Eli Lilly and Company
  • Endocyte Inc
  • EntreChem SL
  • Epigen Biosciences Inc
  • Esperance Pharmaceuticals Inc
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Five Prime Therapeutics Inc
  • Fujifilm Corp
  • Galena Biopharma Inc
  • GamaMabs Pharma SA
  • Ganymed Pharmaceuticals AG
  • Gene Techno Science Co Ltd
  • Genelux Corp
  • Genentech Inc
  • Generex Biotechnology Corp
  • Genisphere Inc
  • Genmab A/S
  • Genor BioPharma Co Ltd
  • Gero Corp
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • GlycoNex Inc
  • Glycotope GmbH
  • GP Pharm SA
  • Gradalis Inc
  • GW Pharmaceuticals Plc
  • Halozyme Therapeutics Inc
  • Hanmi Pharmaceuticals Co Ltd
  • HEC Pharm Co Ltd
  • Hemispherx Biopharma Inc
  • Horizon Pharma Plc
  • Ideaya Biosciences Inc
  • Ignyta Inc
  • Ildong Pharmaceutical Co Ltd
  • IMMD Inc
  • Immune Design Corp
  • Immune Pharmaceuticals Inc
  • Immune Therapeutics Inc
  • Immunocore Ltd
  • ImmunoGen Inc
  • Immunomedics Inc
  • Immunovaccine Inc
  • Incyte Corp
  • Inflection Biosciences Ltd
  • Innate Immunotherapeutics Ltd
  • Innate Pharma SA
  • Inovio Pharmaceuticals Inc
  • INSYS Therapeutics Inc
  • Inventiva
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • Komipharm International Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Laboratoire HRA Pharma
  • Lantern Pharma Inc
  • LegoChem Biosciences Inc
  • Lidds AB
  • Lion Biotechnologies Inc
  • Lixte Biotechnology Holdings Inc
  • Lymphocyte Activation Technologies SA
  • Mabion SA
  • MabVax Therapeutics Holdings Inc
  • MacroGenics Inc
  • Mateon Therapeutics Inc
  • MaxiVAX SA
  • Mebiopharm Co Ltd
  • Medestea Research & Production SpA
  • MediaPharma srl
  • MedImmune LLC
  • Medivation Inc
  • Merck & Co Inc
  • Merck KGaA
  • Mersana Therapeutics Inc
  • Merus NV
  • Microlin Bio, Inc.
  • Millennium Pharmaceuticals Inc
  • Minerva Biotechnologies Corp
  • Molecular Partners AG
  • Moleculin Biotech Inc
  • MolMed SpA
  • Monopar Therapeutics LLC
  • Morphotek Inc
  • Mycenax Biotech Inc
  • Natco Pharma Ltd
  • Nektar Therapeutics
  • Nemucore Medical Innovations Inc
  • Neovacs SA
  • Nerviano Medical Sciences Srl
  • Neurimmune Holding AG
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • NovaTarg Therapeutics Inc
  • Noviga Research AB
  • Novogen Ltd
  • NuCana BioMed Ltd
  • Oasmia Pharmaceutical AB
  • OBI Pharma Inc
  • Omeros Corp
  • Omnitura Therapeutics Inc
  • OncBioMune Pharmaceuticals Inc
  • Oncobiologics Inc
  • Oncodesign SA
  • OncoHoldings Inc
  • Oncolix Inc
  • Oncolytics Biotech Inc
  • OncoMed Pharmaceuticals Inc
  • Oncopeptides AB
  • OncoTartis Inc
  • Oncternal Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Optimum Therapeutics LLC
  • ORCA Therapeutics BV
  • OSE Immunotherapeutics
  • Oxford BioMedica Plc
  • OXIS International Inc
  • Pangaea Biotech SL
  • Panther Biotechnology Inc
  • Patrys Ltd
  • PDS Biotechnology Corp
  • PEP-Therapy SAS
  • Pfizer Inc
  • Pharma Mar SA
  • PharmAust Ltd
  • Pharmicell Co Ltd
  • Plexxikon Inc
  • Polaris Pharmaceuticals Inc
  • Precision Biologics Inc
  • Prima BioMed Ltd
  • Propanc Health Group Corp
  • PsiOxus Therapeutics Ltd
  • Puma Biotechnology Inc
  • Radius Health Inc
  • Recepta Biopharma SA
  • Rexahn Pharmaceuticals Inc
  • Rgenix Inc
  • Richter Gedeon Nyrt
  • Rigontec GmbH
  • Rosetta Genomics Ltd
  • Sanofi
  • Sanofi Pasteur SA
  • Sapvax
  • SATT North SAS
  • Sellas Inc
  • Senhwa Biosciences Inc
  • Shenzen SiBiono GeneTech Co Ltd
  • Siamab Therapeutics Inc
  • Sigma-Tau SpA
  • SOM Biotech SL
  • Soricimed Biopharma Inc
  • Sorrento Therapeutics Inc
  • Sotio as
  • Spectrum Pharmaceuticals Inc
  • Sphaera Pharma Pvt Ltd
  • Starpharma Holdings Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll